Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893509 | 0.79 | GRIN2B (0.44) | ACACBACHE | |
| SCHEMBL19464691 | 0.79 | ACACB (0.38) | ACACBPARP15PARP10PARP2ACHE | |
| SCHEMBL18122046 | 0.79 | ACACB (0.41) | ACACBKDM1APARP15PARP10PARP2 | |
| SCHEMBL20732648 | 0.76 | TDP1 (0.45) | ACACBKDM1A | |
| SCHEMBL12701418 | 0.76 | ACACB (0.39) | ACACBPARP15PARP10PARP2ACHE | |
| SCHEMBL18118645 | 0.76 | EP300 (0.40) | ACACBEP300 | |
| SCHEMBL18112746 | 0.76 | GRIN2B (0.44) | ACACBPARP15PARP10PARP2RIPK1 | |
| SCHEMBL18120349 | 0.75 | EP300 (0.41) | ACACBEP300RIPK1 | |
| SCHEMBL15139202 | 0.75 | ACACB (0.40) | ACACBPARP15PARP10PARP2ACHE | |
| SCHEMBL19987496 | 0.75 | ACACB (0.36) | ACACBPARP15PARP10PARP2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2021-06-01 | — | — | US | disclosed |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2020-07-23 | — | — | US | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| CN-108093636-A | Indoleamine 2, 3-dioxygenase inhibitors for the treatment of cancer | 百时美施贵宝公司 | 2018-05-29 | — | — | CN | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| CN-107743481-A | Indoleamine 2, 3-dioxygenase inhibitors for the treatment of cancer | 百时美施贵宝公司 | 2018-02-27 | — | — | CN | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20140315882-A1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| CN-103998432-A | Bicyclic compounds | TAKEDA PHARMACEUTICAL | 2014-08-20 | — | — | CN | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | ACACB 411/4885EP300 444/4885KDM1A 105/4885 |
| US-11020381-B2 | Biaryloxy derivatives as TTX-S blockers | SCN1B, SCN3A, SCN2B | ACACB 1099/4885EP300 1517/4885KDM1A 2940/4885 |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | P2RX5, P2RX3, ABCG2 | ACACB 2721/4885EP300 37/4885KDM1A 3289/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | ACACB 347/4885EP300 629/4885KDM1A 100/4885 |
| US-20140315882-A1 | PYRIMIDINE-SUBSTITUTED PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TYMP, APRT, TYMS | ACACB 3939/4885EP300 1937/4885KDM1A 3509/4885 |
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ACACB 1112/4885EP300 59/4885KDM1A 1508/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | ACACB 347/4885EP300 629/4885KDM1A 100/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | ACACB 347/4885EP300 629/4885KDM1A 100/4885 |
| US-20200230123-A1 | BIARYLOXY DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN3A, SCN2B | ACACB 1099/4885EP300 1517/4885KDM1A 2940/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | ACACB 347/4885EP300 629/4885KDM1A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.